S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:CGTX

Cognition Therapeutics Stock Forecast, Price & News

$8.27
-0.65 (-7.29%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.96
$9.16
50-Day Range
N/A
52-Week Range
$7.95
$13.80
Volume
68,793 shs
Average Volume
95,657 shs
Market Capitalization
$182.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Cognition Therapeutics

Cognition Therapeutics Inc.is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics Inc.is based in PURCHASE, N.Y.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
N/A
Current Symbol
NASDAQ:CGTX
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$182.24 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/16/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/17/2022

MarketRank

Overall MarketRank

2.18 out of 5 stars

Biological Products, Except Diagnostic Industry

66th out of 201 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.7 5 -4 -3 -2 -1 -












Cognition Therapeutics (NASDAQ:CGTX) Frequently Asked Questions

Is Cognition Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cognition Therapeutics stock.
View analyst ratings for Cognition Therapeutics
or view top-rated stocks.

When is Cognition Therapeutics' next earnings date?

Cognition Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Cognition Therapeutics
.

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics Inc (NASDAQ:CGTX) posted its earnings results on Tuesday, November, 16th. The company reported ($8.12) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $7.55.
View Cognition Therapeutics' earnings history
.

What price target have analysts set for CGTX?

2 analysts have issued 12 month price targets for Cognition Therapeutics' stock. Their forecasts range from $22.00 to $27.00. On average, they expect Cognition Therapeutics' share price to reach $24.50 in the next twelve months. This suggests a possible upside of 196.3% from the stock's current price.
View analysts' price targets for Cognition Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Cognition Therapeutics IPO?

(CGTX) raised $45 million in an IPO on Friday, October 8th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share.

What is Cognition Therapeutics' stock symbol?

Cognition Therapeutics trades on the NASDAQ under the ticker symbol "CGTX."

When did Cognition Therapeutics' quiet period expire?

Cognition Therapeutics' quiet period expired on Wednesday, November 17th. Cognition Therapeutics had issued 3,768,116 shares in its IPO on October 8th. The total size of the offering was $45,217,392 based on an initial share price of $12.00. During Cognition Therapeutics' quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cognition Therapeutics' stock price today?

One share of CGTX stock can currently be purchased for approximately $8.27.

How much money does Cognition Therapeutics make?

Cognition Therapeutics has a market capitalization of $182.24 million.

How many employees does Cognition Therapeutics have?

Cognition Therapeutics employs 2,021 workers across the globe.

What is Cognition Therapeutics' official website?

The official website for Cognition Therapeutics is www.cogrx.com.

How can I contact Cognition Therapeutics?

The company can be reached via phone at 412-481-2210 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.